X4 PHARMACEUTICALS INC · Data as of 2026-09-08
Q3 2026
We plan to meet with the U.S. Food and Drug Administration ("FDA") to revisit the sample size of the 4WARD trial and expect to provide an update on our meeting with the FDA and the completion of enrollment by the end of the third quarter.Source filing
H2 2027
We are targeting completion of enrollment in 4WARD in the third quarter of 2026 and expect to provide top-line data from our 4WARD trial in the second half of 2027.Source filing
Late 2028
With a strengthened cash runway to the end of 2028, X4 is now expected to be able to complete the 4WARD trial, file a potential sNDA for the chronic neutropenia indication, and, if successful, launch mavorixafor in this new indication by the end of 2028.Source filing